Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Insulin-degrading enzyme (IDE), also known as insulysin, is a highly conserved 110-kDa zinc-metallopeptidase that functions primarily in the degradation of insulin, glucagon, and amyloid-beta peptides (UniProt P14735). Beyond its metabolic roles, IDE has been identified as a critical host cell receptor for the Varicella-Zoster Virus (VZV), where it interacts with the viral glycoprotein E (gE) to facilitate viral entry and cell-to-cell spread. The enzyme is ubiquitously expressed, with high concentrations in the liver, skeletal muscle, and brain, reflecting its importance in systemic glucose homeostasis and neuroprotection. In the context of disease, IDE dysfunction is strongly linked to type 2 diabetes due to its role in insulin clearance, and to Alzheimer's disease, where its failure to clear amyloid-beta contributes to plaque formation. As a therapeutic target, IDE presents a unique challenge: while inhibiting IDE could potentially treat diabetes by prolonging insulin signaling, such inhibition might simultaneously increase the risk of amyloid accumulation in the brain. Conversely, blocking the IDE-VZV gE interaction offers a potential pathway for novel antiviral therapies against shingles and chickenpox. Experimental small-molecule inhibitors, such as 6b-K and IDE-inhibitor 1, are currently being used to explore these complex therapeutic trade-offs and the enzyme's potential as a drug target.
Degrades insulin and amyloid-beta peptides via its zinc-metalloprotease activity; serves as a host cell receptor for VZV gE to facilitate viral entry into host cells.
2 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin-degrading enzyme (IDE) (IDE).